BioSpace News Archive

Avadel Pharmaceuticals plc announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company’s financial results for the first quarter ended March 31, 2024.

Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced an oral presentation on the company’s proprietary AURIGIN™ platform at the AI in Biomedicine Keystone Symposia held May 1-3, 2024.

CytomX Therapeutics, Inc. today announced that it will report first quarter 2024 results and provide an initial CX-904 Phase 1a dose escalation update on Wednesday, May 8, 2024, after the close of U.S. markets.

Cocrystal Pharma, Inc. announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements of its novel, broad-spectrum, oral PB2 inhibitor CC-42344.

Benitec Biopharma Inc. today announced that members of Benitec management will participate in Citizens JMP Life Science Conference, taking place in New York, NY from May 13-14, 2024.

Akari Therapeutics, Plc and Peak Bio Inc. announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak’s ADC platform technology and Akari’s PAS-nomacopan Geographic Atrophy program.

Avalyn Pharma Inc. today announced that Douglas Carlson has been appointed chief financial officer and chief business officer.

PharmaTher Holdings Ltd. announced today Sairiyo Therapeutics Inc. has completed its clinical and regulatory package to evaluate Sairiyo’s patented reformulated enteric coated version of orally bioavailable cepharanthine (“PD-001”) as a potential treatment for infectious diseases and oncology in a Phase1 clinical study in Australia.

Lipocine Inc. today announced that dosing of subjects has been completed in the pivotal pharmacokinetic (PK) study designed to support a New Drug Application (NDA) for LPCN 1154.

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), the company’s interchangeable* biosimilar to Humira® (adalimumab), to treat multiple chronic inflammatory diseases.